Weight-Loss Medicines, Contraception and HRT: What Women Need to Know

Last reviewed: 4 September 2026

Medicines such as tirzepatide and semaglutide have changed the way obesity and type 2 diabetes can be managed. They are increasingly used by women who are also taking contraception, hormone replacement therapy, or both.

That has created an important question:

Can weight-management medicines affect the absorption or effectiveness of contraception or HRT?

The answer is slightly more complicated than simply saying yes or no.

For most non-oral hormonal treatments there is little reason for concern. However, oral contraception requires particular attention with tirzepatide, while women taking oral progesterone as part of HRT may also need their treatment reviewed when starting or increasing tirzepatide or semaglutide.

The advice is not identical for every medicine.

First, what medicines are we talking about?

Two of the medicines most commonly discussed are tirzepatide, known by the brand name Mounjaro, and semaglutide, which includes Wegovy.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts on both GLP-1 and GIP receptors.

Among their effects, these medicines alter appetite and gastrointestinal function. Importantly for this discussion, they can slow gastric emptying, meaning that food and medicines may remain in the stomach for longer before reaching the small intestine.

The effect is particularly relevant when a medicine needs to be absorbed through the gastrointestinal tract.

Tirzepatide has a documented effect on the absorption profile of some oral medicines, especially around the time treatment is first started. The effect on gastric emptying generally becomes less pronounced with continued treatment.

This is why the route by which another medicine is given matters so much.

A patch, coil or implant does not have to pass through the stomach. A tablet does.

Mounjaro, tirzepatide and the contraceptive pill

This is currently the area where the UK guidance is clearest.

Studies involving tirzepatide found that a single 5 mg dose altered the absorption of a combined oral contraceptive containing ethinylestradiol and norgestimate. Peak concentrations were substantially reduced and overall drug exposure was reduced by approximately 20% for the hormonal components studied.

There is therefore concern that oral contraception could be less reliable, particularly in women who are overweight or living with obesity.

Current MHRA and sexual-health guidance advises that women taking oral contraception while using tirzepatide should use an additional barrier method, such as condoms, for four weeks after starting tirzepatide and for four weeks after every dose increase.

Alternatively, a non-oral contraceptive method can be considered.

This applies to oral contraception generally, not only the combined pill.

So it is relevant if you take:

the combined contraceptive pill or an oral progestogen-only pill, including desogestrel.

You should not simply stop your existing contraceptive pill. Continue taking it correctly while using the additional contraception advised, unless your clinician recommends changing your contraceptive method altogether.

What about Wegovy or semaglutide?

Semaglutide is different.

Current evidence does not demonstrate a clinically significant reduction in the effectiveness of oral contraception with semaglutide.

Studies assessing ethinylestradiol and levonorgestrel found no clinically important reduction in overall exposure when taken alongside semaglutide. The current Wegovy product information therefore states that semaglutide is not expected to reduce the effectiveness of oral contraception.

The College of Sexual and Reproductive Healthcare, formerly the FSRH, similarly states that there is currently no evidence that semaglutide reduces the effectiveness of combined or progestogen-only oral contraception.

This distinction is important.

The specific four-week additional contraception rule applies to tirzepatide rather than semaglutide.

Since June 2026, an oral semaglutide formulation of Wegovy has also been authorised in the UK for weight management. Pharmacokinetic studies for oral semaglutide have similarly not demonstrated a clinically relevant effect on the exposure of the oral contraceptive studied.

Patients using oral semaglutide must, however, follow the administration instructions for that medicine carefully because its own absorption can be affected by food, drink and other tablets.

Vomiting and diarrhoea can create another problem

There is another issue that applies regardless of whether the medicine itself interacts with contraception.

Nausea, vomiting and diarrhoea are common adverse effects of GLP-1-based treatments, particularly when treatment is started or the dose is increased.

If you vomit shortly after taking an oral contraceptive tablet, the tablet may not have been adequately absorbed.

Similarly, significant or persistent diarrhoea can make oral contraception less reliable.

Current sexual-health guidance recommends following the missed-pill instructions for your particular contraceptive if vomiting occurs soon after taking the pill or if severe diarrhoea continues for more than 24 hours. Persistent gastrointestinal symptoms may be another reason to consider a non-oral contraceptive method.

The exact missed-pill rules vary depending on which pill you take, so check the patient information leaflet or speak to a pharmacist, prescriber or sexual-health clinician.

Are the coil, implant, injection, patch or vaginal ring affected?

This part is considerably simpler.

There is no reason to expect GLP-1 medicines to reduce the effectiveness of contraceptive methods that do not rely on gastrointestinal absorption.

The College of Sexual and Reproductive Healthcare advises that non-oral contraceptive methods are not expected to be affected by GLP-1 medicines.

That includes contraceptive implants, hormonal and copper coils, injections, contraceptive patches and vaginal rings.

For someone expecting several increases in tirzepatide dose, a non-oral method may therefore be more convenient than repeatedly needing four-week periods of additional barrier contraception.

That does not mean everybody needs to change contraception. Choice of contraception remains individual and should take into account effectiveness, bleeding patterns, medical history, personal preference and plans for pregnancy.

What if emergency contraception is needed?

The evidence here is less certain.

There are currently no direct pharmacokinetic studies showing exactly how GLP-1 medicines affect oral emergency contraception.

For that reason, anyone requiring emergency contraception while taking tirzepatide, semaglutide or another GLP-1 medicine should tell the pharmacist, doctor or sexual-health clinician assessing them.

The copper intrauterine device, or copper coil, remains the most effective form of emergency contraception and its effectiveness is not affected by delayed gastric emptying, vomiting or diarrhoea.

Where oral emergency contraception is being considered, other factors also matter.

For example, existing UK guidance advises considering an increased dose of levonorgestrel emergency contraception in women weighing more than 70 kg or with a BMI above 26 kg/m². This recommendation relates to body weight and BMI rather than specifically to GLP-1 treatment.

Emergency contraception is therefore an area where individual assessment is particularly important.

And then we come to HRT

This is probably the area creating the most confusion.

A woman might be using an oestrogen patch or gel alongside oral micronised progesterone while also starting semaglutide or tirzepatide.

It is easy to assume that because the oestrogen is being absorbed properly through the skin, the whole HRT regimen is unaffected.

That is not necessarily the case.

For women who still have a uterus, the progesterone or progestogen component of HRT is extremely important because it protects the endometrium, the lining of the womb, from the effects of oestrogen.

Oral micronised progesterone is absorbed through the gastrointestinal tract.

The British Menopause Society therefore identifies potentially reduced absorption of oral progesterone or oral progestogens as the principal concern when HRT is being used alongside semaglutide or tirzepatide.

Importantly, this is an area where the evidence is still limited.

There are not currently good clinical trials demonstrating that women taking GLP-1 medicines experience inadequate endometrial protection from their usual progesterone dose.

The concern is pharmacological and precautionary, with recommendations partly extrapolated from the effect seen with oral contraceptives.

That uncertainty needs to be made clear.

Do women taking HRT need to double their progesterone?

This has become one of the most common questions.

There is currently no blanket UK recommendation telling every woman taking semaglutide or tirzepatide to automatically double her progesterone dose.

The British Menopause Society takes a more nuanced approach.

For women using an oral progesterone or progestogen, it advises clinicians to consider either changing to a non-oral method of endometrial protection or temporarily increasing the oral progestogen dose when the incretin-based treatment is started and following dose increases.

The period suggested is four weeks following initiation and four weeks following each dose increase.

Crucially, the BMS also acknowledges that there are insufficient data to establish exactly what the dose increase should be. The recommendation is based on expert opinion and extrapolation rather than a trial demonstrating that a particular increased dose is necessary or optimal.

So the message should not be:

“Everybody taking a weight-loss injection must double their progesterone.”

The better message is:

If you use oral progesterone or another oral progestogen as part of HRT and you are starting or increasing semaglutide or tirzepatide, your HRT regimen should be reviewed.

The appropriate option depends on your oestrogen dose, progesterone regimen, uterus status, bleeding pattern, risk factors and personal preferences.

Patients should not alter their HRT dose without discussing it with their prescriber.

What about oestrogen?

Where appropriate, the British Menopause Society favours transdermal oestrogen, such as patches, gels or sprays, in women living with obesity or diabetes.

There are two reasons.

Firstly, absorption through the skin avoids the gastrointestinal tract and is therefore not affected by delayed gastric emptying.

Secondly, transdermal oestrogen has a more favourable thrombotic risk profile than oral oestrogen, which can be particularly relevant where obesity or other cardiovascular risk factors are present.

This does not mean that every woman taking oral HRT must automatically change treatment, but it is sensible to review the route when GLP-1 treatment is commenced.

The hormonal coil can solve several problems at once

For a perimenopausal woman who still requires contraception and also uses oestrogen as part of HRT, a 52 mg levonorgestrel-releasing intrauterine device can be particularly useful.

It provides highly effective contraception while also providing endometrial protection for the oestrogen component of HRT.

Because the hormone acts locally and does not rely on gastrointestinal absorption, the British Menopause Society considers this an attractive option for women taking semaglutide or tirzepatide.

When being used for endometrial protection as part of HRT, the device should be replaced according to the relevant HRT guidance, currently at five years.

It will not be suitable or desirable for everybody, but it is an option worth discussing.

What about combined HRT patches?

A combined HRT patch already delivers both the oestrogen and progestogen without relying on gastrointestinal absorption.

The British Menopause Society’s current pragmatic guidance therefore recommends no change purely because semaglutide or tirzepatide has been started.

The same principle applies to the endometrial protection provided by a suitable 52 mg levonorgestrel intrauterine system.

Vaginal progesterone is also unlikely to be affected by delayed gastric emptying, although vaginal use of micronised progesterone for HRT remains outside its UK licence and therefore requires an individual clinical decision.

Unscheduled bleeding should not simply be ignored

Changes to HRT, weight, hormone absorption and the menopause transition itself can all alter bleeding patterns.

Some unscheduled bleeding is common after starting or changing HRT.

However, persistent, recurrent, heavy or otherwise concerning bleeding should not simply be blamed on the GLP-1 medicine.

Current national guidance recommends assessing the bleeding pattern, HRT regimen, adherence and individual risk factors and undertaking further investigation where indicated. The joint British Menopause Society guideline on unscheduled bleeding was reviewed again in May 2026.

This becomes particularly relevant if there is any concern that oral progesterone may not be providing adequate endometrial protection.

Pregnancy and GLP-1 medicines

These medicines should not be used during pregnancy.

Current MHRA advice is that people who could become pregnant should use effective contraception while taking them.

For a planned pregnancy, there is also a washout period.

These recommendations reflect how long the medicines remain in the body.

Anyone who becomes pregnant while taking one of these medicines should stop treatment and speak to their healthcare professional promptly.

Current MHRA advice also recommends avoiding GLP-1 medicines while breastfeeding because there remains insufficient safety information.

The practical message

There is a tendency for information online to become oversimplified.

“Mounjaro stops the pill working” is too simplistic.

“GLP-1 medicines do not interact with HRT” is also too simplistic.

And “everyone needs to double their progesterone” is not supported by the available evidence.

What matters is which medicine you are taking, which hormonal treatment you use, how it is administered and where you are in the dose-escalation process.

Tirzepatide requires additional contraceptive precautions with oral contraception after treatment is started and after each dose increase.

Semaglutide does not currently appear to reduce oral contraceptive effectiveness.

Non-oral contraception is not expected to be affected by either.

For HRT, the principal concern is adequate endometrial protection in women using oral progesterone or another oral progestogen, and current British Menopause Society advice supports reviewing these regimens when semaglutide or tirzepatide is introduced.

That review should be individual rather than automatic.

If you take contraception or HRT alongside a weight-management or diabetes medicine and are unsure whether your treatment needs changing, speak to a pharmacist, GP, menopause clinician, sexual-health professional or your usual prescriber before altering either medicine.

References and further reading

1. MHRA, GLP-1 medicines for weight loss and diabetes: what you need to know, updated 5 February 2026. MHRA guidance on GLP-1 medicines
2. College of Sexual and Reproductive Healthcare, formerly FSRH, GLP-1 agonists and contraception, clinical statement and patient information.
3. British Menopause Society, Use of incretin-based therapies in women using hormone replacement therapy, Tool for Clinicians, April 2025. British Menopause Society clinical resource
4. British Menopause Society and partner organisations, Management of unscheduled bleeding on HRT, reviewed May 2026. BMS unscheduled bleeding guidance
5. Electronic Medicines Compendium, tirzepatide Summary of Product Characteristics.
6. Electronic Medicines Compendium, semaglutide/Wegovy Summary of Product Characteristics.
7. MHRA, First GLP-1 tablet for weight loss approved in the UK, 11 June 2026. MHRA announcement on oral semaglutide

Important information

This article was reviewed on 4 September 2026 and reflects UK guidance and product information available on that date.

Medical evidence, product licences, regulatory advice and professional guidelines can change. Bramley Pharmacy and Murrays Chemist do not undertake to retrospectively amend every published article each time guidance changes. Readers should therefore check current guidance and obtain individual advice from an appropriately qualified healthcare professional before making changes to prescribed medicines, contraception or HRT.

This article is provided for general educational purposes and is not intended to replace an individual medical consultation. Prescription-only medicines mentioned within this article are discussed solely in the context of factual clinical and medicines-safety information. Their inclusion does not constitute a recommendation or promotion of a particular prescription medicine. Suitability for any prescription treatment must be determined following an appropriate clinical assessment.